drugset / Trial / NCT02715505

Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)

NCT02715505

Phase 1/2 Withdrawn Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the safety and exploratory efficacy of using HSC835 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.

Timeline

Start
2017-10-10
Primary completion
2020-05-18
Completion
2020-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject HSC835 Cell therapy